Relmada Therapeutics, Inc. RLMD Programming obligations
Programming obligations at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProgramRightsObligationsNoncurrent.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s programming obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s programming obligations?
- Relmada Therapeutics, Inc. (RLMD) reported programming obligations of $3.74M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s programming obligations changed year-over-year?
- Relmada Therapeutics, Inc.'s programming obligations increased by 49714.6% year-over-year, from $7.51K to $3.74M.
- What does programming obligations mean?
- Represents long-term contractual commitments or financial obligations related to the licensing, development, or commercialization rights of specific drug programs. These obligations often arise from collaboration agreements or intellectual property acquisitions that extend beyond the current fiscal year. Monitoring these helps investors assess the long-term capital requirements and potential future cash outflows associated with the company's pipeline.